Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16

Protection to sexually transmitted infections with oncogenic human papillom aviruses (HPV) such as type 16 is thought to be provided by neutralizing an tibodies directed to the major outer capsid protein, the L1 protein. A DNA vaccine and an E1-deleted adenoviral recombinant human strain 5, both expre ssing the L1 protein of HPV-16, were developed and shown to express L1 prot ein able to assemble into virus-like particles (VLPs). The vaccines used in a prime-boost regimen, with the DNA given intramuscularly (i.m.) for primi ng, followed by an intranasal (i.n.) booster immunization with the viral re combinant, induced antibodies to Li in sera and in vaginal secretions. (C) 2001 Elsevier Science Ltd. All rights reserved.